Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of F2695 on Brain Activity
NCT02266966Phase 1Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing F2695 with Placebo (2 arms). Primary endpoint: Motor system cortical areas activation magnitude during a paced motor task at 1 day. Started Apr 2014; status: completed.
02
Drugs
levomilnacipran
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02266966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266966.